STIM’s sales for 2023 have already exceeded the $110 million recorded last year.
Investment company Nordly Holding has initiated a strategic review of its ownership stake in fish health company STIM, signalling the possibility of bringing in new owners.
The review process will be spearheaded by financial services group ABG Sundal Collier, the holding firm announced in a press release on Friday.
With offices in Norway, Chile, the United Kingdom, and Canada, STIM’s diverse portfolio includes the supply of pharmaceuticals, fish health products, environmental surveys, and consulting services.
STIM’s NOK 1,206 billion ($110 million) sales record for last year was already surpassed in September this year, underscoring the firm’s impressive growth trajectory.
Jim-Roger Nordly, CEO and owner of Nordly Holding, emphasized STIM’s expansive biological expertise and significant role in the global aquaculture industry. “Virtually all of the world’s salmon farmers are on our customer lists today,” Nordly stated, highlighting STIM’s robust position fueled by rising activity and annual sales.
The strategic review of Nordly Holding’s ownership in STIM is anticipated to conclude in the first half of 2024. Nordly expressed confidence in the process, emphasizing the necessity of identifying owners who align with STIM’s values and possess the competence and ambition to elevate the company further.
